RxDoctor Payments Data

Lynda Artusio

Psychiatric/Mental Health · Frederick, MDNPI 1841363702

Payments from drug & device makers

$2,133in general payments, 2019–2025

Across 102 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$395
  • AbbVie$282
  • Neurocrine Biosciences, Inc.$217
  • Supernus Pharmaceuticals, Inc.$182
  • Otsuka America Pharmaceutical, Inc.$147
  • Axsome Therapeutics, Inc.$146
  • plus $764 from 14 others

What the payments were for

  • Food & beverage$2,05796%
  • Education$764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,133 in reported general payments places this provider in the 85th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$41,725
Medicare patients
108
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$23,947
Aripiprazole72$12,993
Lurasidone Hcl27$9,187
Bupropion XlBupropion Hcl85$3,943
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine24$2,084
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$1,563
Clonazepam191$1,453
Duloxetine Hcl53$1,452
Escitalopram Oxalate79$1,261
Venlafaxine Hcl ErVenlafaxine Hcl58$1,249
Lorazepam148$1,120
Buspirone Hcl51$1,084
Trazodone Hcl87$969
Gabapentin58$907
Mirtazapine41$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$282$23,94712 claims
Almatica Pharma LLCSertraline Hcl$17$60539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →